SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corp. (AMEX:INO), which is focused on the development of DNA-based immunotherapy products and a novel tumor ablation therapy, announced today that its Executive Director of Corporate Development, Dr. Michael Fons, will present new developments in Inovio’s DNA immunotherapy programs at the Arrowhead Drug Delivery 2007 conference to be held April 9 to 11 at the Crowne Plaza Union Square in San Francisco, CA. Dr. Fons’ presentation will cover key aspects of non-viral DNA delivery via electroporation of four different partnered immunotherapy products that are currently in clinical evaluation for cancers including prostate, breast, ovarian, colorectal, melanoma and small cell lung cancer. The presentation will reference pre-clinical studies demonstrating safety and efficacy in animal models of cancer and infectious diseases and highlights of the regulatory approach used to permit clinical evaluation of these novel drug-device combination therapeutic products.
